Professor Nils Brünner, MD, DMSc trained in Internal Medicine and Medical Oncology in Copenhagen and, in addition in Molecular and Cellular Biology at the National Cancer Institute and the Lombardi Cancer Research Centre, Washington DC. He became Professor at the Faculty of Health and Medical Sciences, University of Copenhagen in 2002 and is presently at Institute of Drug Design and Pharmacology, University of Copenhagen. At the same time, he is Unit Head, Translational Cancer Research at the Danish Cancer Society Research facilities. He also is presently CEO of Scandion Oncology, Denmark
Dr. Brünner’s main research interests are in Personalized Preventive Cancer Medicine and specifically in prognostic and predictive biomarkers in pre-malignant and malignant diseases. He is now focusing on drug resistance in cancer. More recently, this has led to innovative work in the identification and of novel anti-cancer drugs which work in the clinical setting of the development of drug resistance.
His work on the Indenoisoquinoline LMP400 with Dr. Yves Pommier, Head of Molecular Oncology at the National Cancer Institute, led to the observation of LMP400’s ability to still kill cancer cells when other drugs have developed drug resistance. He demonstrated that metastatic colon cancer cells made unresponsive to Irinotecan still respond to LMP400.
Dr. Brünner has published more than 370 scientific papers, most of which deal with translational cancer research.
Gibson Oncology,LLC is composed of proven academic researchers and bio tech entrepreneurs who are excited to be developing effective and safer novel oncology drugs to treat resistant cancers with a focus on children.